These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19414584)

  • 1. Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.
    Abduljalil K; Kinzig M; Bulitta J; Horkovics-Kovats S; Sörgel F; Rodamer M; Fuhr U
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2892-901. PubMed ID: 19414584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.
    Ikawa K; Kikuchi E; Kikuchi J; Nishimura M; Derendorf H; Morikawa N
    J Clin Pharm Ther; 2014 Aug; 39(4):411-7. PubMed ID: 24661290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects.
    Lee CM; Jung EH; Byeon JY; Kim SH; Jang CG; Lee YJ; Lee SY
    Arch Pharm Res; 2019 Dec; 42(12):1101-1106. PubMed ID: 31820397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tolerability of extended-release clarithromycin.
    Guay DR; Gustavson LE; Devcich KJ; Zhang J; Cao G; Olson CA
    Clin Ther; 2001 Apr; 23(4):566-77. PubMed ID: 11354390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers.
    Kees F; Wellenhofer M; Grobecker H
    Infection; 1995; 23(3):168-72. PubMed ID: 7499006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.
    Traunmüller F; Zeitlinger M; Zeleny P; Müller M; Joukhadar C
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3185-9. PubMed ID: 17606673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.
    Fish DN; Abraham E
    Antimicrob Agents Chemother; 1999 May; 43(5):1277-80. PubMed ID: 10223952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults.
    Guay DR; Craft JC
    Pediatr Infect Dis J; 1993 Dec; 12(12 Suppl 3):S106-11. PubMed ID: 8295810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.
    Carr RA; Edmonds A; Shi H; Locke CS; Gustavson LE; Craft JC; Harris SI; Palmer R
    Antimicrob Agents Chemother; 1998 May; 42(5):1176-80. PubMed ID: 9593146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.
    Chu S; Wilson DS; Deaton RL; Mackenthun AV; Eason CN; Cavanaugh JH
    J Clin Pharmacol; 1993 Aug; 33(8):719-26. PubMed ID: 8408732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarithromycin pharmacokinetics in healthy young and elderly volunteers.
    Chu SY; Wilson DS; Guay DR; Craft C
    J Clin Pharmacol; 1992 Nov; 32(11):1045-9. PubMed ID: 1474166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
    Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE
    Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.
    Kikuchi E; Yamazaki K; Kikuchi J; Hasegawa N; Hashimoto S; Ishizaka A; Nishimura M
    Respirology; 2008 Mar; 13(2):221-6. PubMed ID: 18339019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
    Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
    Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
    Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
    Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals.
    Womble AY; Giguère S; Lee EA; Vickroy TW
    Am J Vet Res; 2006 Oct; 67(10):1681-6. PubMed ID: 17014316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.
    Gotfried MH; Danziger LH; Rodvold KA
    J Antimicrob Chemother; 2003 Sep; 52(3):450-6. PubMed ID: 12888589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
    Posada MM; Morse BL; Turner PK; Kulanthaivel P; Hall SD; Dickinson GL
    J Clin Pharmacol; 2020 Jul; 60(7):915-930. PubMed ID: 32080863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between ritonavir and clarithromycin.
    Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
    Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of oral clarithromycin in foals.
    Jacks S; Giguère S; Gronwall RR; Brown MP; Merritt KA
    J Vet Pharmacol Ther; 2002 Oct; 25(5):359-62. PubMed ID: 12423226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.